JP2016513644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513644A5 JP2016513644A5 JP2016501386A JP2016501386A JP2016513644A5 JP 2016513644 A5 JP2016513644 A5 JP 2016513644A5 JP 2016501386 A JP2016501386 A JP 2016501386A JP 2016501386 A JP2016501386 A JP 2016501386A JP 2016513644 A5 JP2016513644 A5 JP 2016513644A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- pharmaceutical composition
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 47
- 108010067003 Interleukin-33 Proteins 0.000 claims description 25
- 102000017761 Interleukin-33 Human genes 0.000 claims description 25
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 claims description 8
- 102000045906 human IL33 Human genes 0.000 claims description 8
- 238000010494 dissociation reaction Methods 0.000 claims description 7
- 230000005593 dissociations Effects 0.000 claims description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000005557 antagonist Substances 0.000 claims 12
- 239000013566 allergen Substances 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 102100037850 Interferon gamma Human genes 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 3
- 108010002616 Interleukin-5 Proteins 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 238000010171 animal model Methods 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 210000003651 basophil Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- -1 bronchodilator Substances 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000670 ligand binding assay Methods 0.000 claims 1
- 230000002912 lymphogenic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 238000001525 receptor binding assay Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000002992 thymic effect Effects 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000012146 running buffer Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 101000998136 Mus musculus Interleukin-33 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778687P | 2013-03-13 | 2013-03-13 | |
| US61/778,687 | 2013-03-13 | ||
| US201361819018P | 2013-05-03 | 2013-05-03 | |
| US61/819,018 | 2013-05-03 | ||
| PCT/US2014/023930 WO2014164959A2 (en) | 2013-03-13 | 2014-03-12 | Anti-il-33 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019018423A Division JP6845876B2 (ja) | 2013-03-13 | 2019-02-05 | 抗ｉｌ−３３抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513644A JP2016513644A (ja) | 2016-05-16 |
| JP2016513644A5 true JP2016513644A5 (enExample) | 2017-04-06 |
| JP6479755B2 JP6479755B2 (ja) | 2019-03-06 |
Family
ID=50678269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501386A Active JP6479755B2 (ja) | 2013-03-13 | 2014-03-12 | 抗ｉｌ−３３抗体及びその使用 |
| JP2019018423A Active JP6845876B2 (ja) | 2013-03-13 | 2019-02-05 | 抗ｉｌ−３３抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019018423A Active JP6845876B2 (ja) | 2013-03-13 | 2019-02-05 | 抗ｉｌ−３３抗体及びその使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9453072B2 (enExample) |
| EP (3) | EP3683235B1 (enExample) |
| JP (2) | JP6479755B2 (enExample) |
| KR (1) | KR102103159B1 (enExample) |
| CN (1) | CN105051063B (enExample) |
| AU (1) | AU2014248839B2 (enExample) |
| CA (1) | CA2902172C (enExample) |
| CL (2) | CL2015002469A1 (enExample) |
| DK (2) | DK2970460T3 (enExample) |
| EA (1) | EA031745B1 (enExample) |
| ES (2) | ES2804592T3 (enExample) |
| FI (1) | FI3683235T3 (enExample) |
| HR (2) | HRP20200846T1 (enExample) |
| HU (2) | HUE051018T2 (enExample) |
| IL (2) | IL240354A0 (enExample) |
| JO (1) | JO3532B1 (enExample) |
| LT (2) | LT3683235T (enExample) |
| MX (2) | MX377712B (enExample) |
| MY (3) | MY201923A (enExample) |
| PH (1) | PH12015501656B1 (enExample) |
| PL (2) | PL3683235T3 (enExample) |
| PT (2) | PT3683235T (enExample) |
| RS (2) | RS65586B1 (enExample) |
| SG (1) | SG11201505745WA (enExample) |
| SI (2) | SI3683235T1 (enExample) |
| TW (1) | TWI633119B (enExample) |
| UY (1) | UY35417A (enExample) |
| WO (1) | WO2014164959A2 (enExample) |
| ZA (1) | ZA201505376B (enExample) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2827923C (en) | 2011-02-25 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc antibody |
| JP5997151B2 (ja) | 2011-06-30 | 2016-09-28 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| CA3233142A1 (en) | 2011-11-30 | 2013-06-06 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| WO2013125667A1 (ja) | 2012-02-24 | 2013-08-29 | 中外製薬株式会社 | FcγRIIBを介して抗原の消失を促進する抗原結合分子 |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| IL312711A (en) | 2012-08-21 | 2024-07-01 | Regeneron Pharma | Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL |
| SG11201500873XA (en) | 2012-08-24 | 2015-04-29 | Chugai Pharmaceutical Co Ltd | Fcgriib-specific fc region variant |
| US10766960B2 (en) | 2012-12-27 | 2020-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| KR20150127591A (ko) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
| EP3088517B1 (en) | 2013-12-26 | 2023-11-01 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| RU2693084C2 (ru) * | 2014-01-10 | 2019-07-01 | Анаптисбайо, Инк. | Антитела, направленные против интерлейкина-33 (il-33) |
| CA2946511C (en) | 2014-04-21 | 2023-08-22 | The Childen's Hospital Of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| NO2785538T3 (enExample) * | 2014-05-07 | 2018-08-04 | ||
| EP3201227A4 (en) | 2014-09-29 | 2018-04-18 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
| CN107109494B (zh) * | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| AU2015346460A1 (en) | 2014-11-10 | 2017-03-23 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| HK1247622A1 (zh) * | 2015-03-02 | 2018-09-28 | 180 Therapeutics Lp | 利用il-33拮抗剂来治疗局部纤维化的方法 |
| CN108064236B (zh) * | 2015-03-31 | 2021-12-10 | 免疫医疗有限公司 | 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法 |
| CN113413938B (zh) * | 2015-04-06 | 2023-07-28 | 中尺度技术有限责任公司 | 操作测定系统的方法及ecl免疫测定系统 |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| KR102687412B1 (ko) * | 2015-10-06 | 2024-07-24 | 리제너론 파아마슈티컬스, 인크. | 인터루킨-33(il-33)-매개된 질환과 관련된 바이오마커 및 이의 용도 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CA3011547A1 (en) * | 2016-01-14 | 2017-07-20 | Anaptysbio, Inc. | Inhibition of allergic reaction using an il-33 inhibitor |
| JP7038064B2 (ja) | 2016-04-18 | 2022-03-17 | セルデックス セラピューティクス インコーポレイテッド | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
| US20190119380A1 (en) * | 2016-04-22 | 2019-04-25 | Medimmune, Llc | Functional plasticity of ilc2, immunity, and copd |
| KR20240052871A (ko) | 2016-04-27 | 2024-04-23 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| RU2740309C2 (ru) | 2016-04-27 | 2021-01-13 | Пфайзер Инк. | Антитела против il-33, композиции, способы и их применение |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| US11390676B2 (en) * | 2016-10-13 | 2022-07-19 | Symphogen A/S | Anti-LAG-3 antibodies and compositions |
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| BR112019016595A2 (pt) | 2017-02-10 | 2020-03-31 | Genentech, Inc. | Anticorpos isolados, métodos de produção do anticorpo e de tratamento de um distúrbio, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, composições farmacêuticas e uso |
| CN108456251A (zh) * | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | 抗pd-l1抗体及其应用 |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| JP7321939B2 (ja) * | 2017-04-13 | 2023-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| BR112020000127A2 (pt) | 2017-07-06 | 2020-07-07 | Regeneron Pharmaceuticals, Inc. | método para selecionar um hidrolisado de soja, e, glicoproteína |
| AU2018325645C1 (en) | 2017-08-31 | 2025-01-30 | Hyogo College Of Medicine | IL-33 antagonist-containing therapeutic agent for endometriosis |
| EP3710589A4 (en) | 2017-11-14 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | ANTI-C1S ANTIBODIES AND METHOD OF USING |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| MX2020008095A (es) | 2018-01-31 | 2020-09-24 | Regeneron Pharma | Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos. |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR20230142806A (ko) | 2018-02-09 | 2023-10-11 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3246952A1 (en) | 2018-03-19 | 2025-10-31 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| IL277890B2 (en) * | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| IL317002A (en) | 2018-08-10 | 2025-01-01 | Chugai Pharmaceutical Co Ltd | Anti-CD137 antigen binding molecule and use thereof |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| US11754569B2 (en) | 2018-08-30 | 2023-09-12 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| PL3857237T3 (pl) | 2019-01-16 | 2023-07-10 | Regeneron Pharmaceuticals, Inc. | Sposoby charakteryzowania mostka disiarczkowego |
| TW202519263A (zh) | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| KR20220004708A (ko) * | 2019-05-01 | 2022-01-11 | 사노피 바이오테크놀로지 | Il-33 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| AU2020275406A1 (en) | 2019-05-13 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| CN114096562B (zh) | 2019-05-15 | 2025-02-21 | 中外制药株式会社 | 抗原结合分子、药物组合物和方法 |
| CA3147436A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| IL291020B2 (en) | 2019-09-24 | 2025-04-01 | Regeneron Pharma | Systems and methods for use in chromatography and regeneration |
| WO2021064452A1 (en) | 2019-10-03 | 2021-04-08 | Dasman Diabetes Institute | Method for preventing progression to type ii diabetes |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| JP2023501316A (ja) | 2019-11-04 | 2023-01-18 | メドイミューン・リミテッド | 腎機能障害を治療するための抗ｉｌ－３３治療薬 |
| IL292443A (en) | 2019-11-04 | 2022-06-01 | Medimmune Ltd | Methods for using IL-33 antagonists |
| MY207613A (en) | 2019-11-25 | 2025-03-06 | Regeneron Pharma | Sustained release formulations using non-aqueous emulsions |
| CA3162507A1 (en) * | 2019-12-23 | 2021-07-01 | Helene Goulaouic | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist |
| US11835527B2 (en) | 2020-01-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
| CN115315527A (zh) | 2020-03-13 | 2022-11-08 | 免疫医疗有限公司 | 用于治疗il33中存在风险等位基因的受试者的治疗方法 |
| JP7767298B2 (ja) * | 2020-03-13 | 2025-11-11 | ジェネンテック， インコーポレイテッド | 抗インターロイキン－３３抗体及びその使用 |
| IL296853A (en) | 2020-04-06 | 2022-11-01 | Medimmune Ltd | Treatment of acute respiratory distress syndrome with il-33 axis binding antagonists |
| KR20230002612A (ko) * | 2020-04-13 | 2023-01-05 | 매든 어드바이저스 엘엘씨 | Ace2-표적화 조성물 및 covid-19의 치료 방법 |
| EP4149521A1 (en) | 2020-05-11 | 2023-03-22 | MedImmune Limited | Formulations of anti-il-33 antibodies |
| AU2021271960A1 (en) * | 2020-05-12 | 2023-02-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | ST2 antigen binding protein |
| KR102789102B1 (ko) * | 2020-08-18 | 2025-03-28 | 성균관대학교산학협력단 | Il-33 항체 또는 이의 항원 결합 단편 |
| IL300828A (en) | 2020-08-31 | 2023-04-01 | Regeneron Pharma | Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants |
| CN114249825A (zh) * | 2020-09-25 | 2022-03-29 | 三生国健药业（上海）股份有限公司 | 结合人il-33的抗体、其制备方法和用途 |
| MX2023006077A (es) | 2020-11-25 | 2023-06-06 | Regeneron Pharma | Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa. |
| US12350374B2 (en) | 2020-12-17 | 2025-07-08 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| TW202233827A (zh) | 2021-01-20 | 2022-09-01 | 美商再生元醫藥公司 | 改良細胞培養中蛋白質效價的方法 |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| CA3211302A1 (en) | 2021-03-26 | 2022-09-29 | Ross Kenyon | Methods and systems for developing mixing protocols |
| BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
| CN113493513B (zh) * | 2021-06-30 | 2022-07-12 | 深圳大学 | 抗人il-33中和性自身抗体及其制备方法和应用 |
| CN113603775B (zh) * | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| JP2024538673A (ja) | 2021-10-07 | 2024-10-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ｐＨモデリング及び制御のシステム及び方法 |
| MX2024005090A (es) | 2021-10-26 | 2024-07-19 | Regeneron Pharma | Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas. |
| JP2024544885A (ja) | 2021-11-10 | 2024-12-05 | ジェネンテック， インコーポレイテッド | 抗インターロイキン－３３抗体及びその使用 |
| AU2023227442A1 (en) * | 2022-03-03 | 2024-09-12 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| US20260056210A1 (en) | 2022-08-19 | 2026-02-26 | Medimmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
| CN120418653A (zh) | 2022-12-16 | 2025-08-01 | 里珍纳龙药品有限公司 | 评估色谱柱完整性的方法和系统 |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| KR102773101B1 (ko) | 2023-08-28 | 2025-02-26 | 서울대학교산학협력단 | 세포독성능을 갖는 제2형 선천성 림프구 세포, 이의 제조방법 및 용도 |
| JP7668943B2 (ja) * | 2023-08-30 | 2025-04-25 | ファイザー・インク | 多重特異性抗体およびその使用 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| CN121925272A (zh) | 2023-09-29 | 2026-04-24 | 瑞泽恩制药公司 | 利用受控成核进行冻干 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025120567A1 (en) | 2023-12-07 | 2025-06-12 | Medimmune Limited | Method of treatment of asthma |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025210099A1 (en) | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
| WO2025242618A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Bronchiectasis treatment |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
| WO2026007411A1 (zh) * | 2025-02-11 | 2026-01-08 | 广州医科大学 | 抗IL1RL1/IL-33/NF-kB抗体和使用其治疗急性髓性白血病的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US550362A (en) | 1895-11-26 | crosby | ||
| US1000056A (en) | 1910-11-03 | 1911-08-08 | Carlos Van Bergh | Threshing-machine. |
| US1001164A (en) | 1911-06-09 | 1911-08-22 | Arthur W Porter | Cotton-sweep. |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5576191A (en) | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
| US20070042978A1 (en) | 2002-12-19 | 2007-02-22 | Jean-Philippe Girard | Nf-hev compositions and methods of use |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| US8865645B2 (en) | 2006-05-24 | 2014-10-21 | Biogen Idec Ma Inc. | Method of treating lung fibrosis using ST2 polypeptide |
| NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| IE20080331A1 (en) | 2007-04-26 | 2009-07-08 | Trinity College Dublin | Products for altering cytokine activity and methods therefor |
| CA2686683A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
| CA2703335A1 (en) | 2007-10-26 | 2009-04-30 | Arturo Zychlinsky | Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| KR20150127591A (ko) | 2013-03-15 | 2015-11-17 | 리제너론 파아마슈티컬스, 인크. | Il-33 길항제 및 이의 용도 |
| EP3088517B1 (en) | 2013-12-26 | 2023-11-01 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| RU2693084C2 (ru) | 2014-01-10 | 2019-07-01 | Анаптисбайо, Инк. | Антитела, направленные против интерлейкина-33 (il-33) |
-
2014
- 2014-03-09 JO JOP/2014/0080A patent/JO3532B1/ar active
- 2014-03-11 TW TW103108304A patent/TWI633119B/zh active
- 2014-03-12 SI SI201432077T patent/SI3683235T1/sl unknown
- 2014-03-12 WO PCT/US2014/023930 patent/WO2014164959A2/en not_active Ceased
- 2014-03-12 MX MX2015010599A patent/MX377712B/es active IP Right Grant
- 2014-03-12 EA EA201591716A patent/EA031745B1/ru unknown
- 2014-03-12 LT LTEP20159871.1T patent/LT3683235T/lt unknown
- 2014-03-12 JP JP2016501386A patent/JP6479755B2/ja active Active
- 2014-03-12 HU HUE14722008A patent/HUE051018T2/hu unknown
- 2014-03-12 PL PL20159871.1T patent/PL3683235T3/pl unknown
- 2014-03-12 SI SI201431574T patent/SI2970460T1/sl unknown
- 2014-03-12 RS RS20240631A patent/RS65586B1/sr unknown
- 2014-03-12 AU AU2014248839A patent/AU2014248839B2/en active Active
- 2014-03-12 HR HRP20200846TT patent/HRP20200846T1/hr unknown
- 2014-03-12 HU HUE20159871A patent/HUE067119T2/hu unknown
- 2014-03-12 CA CA2902172A patent/CA2902172C/en active Active
- 2014-03-12 CN CN201480014548.XA patent/CN105051063B/zh active Active
- 2014-03-12 RS RS20200801A patent/RS60503B1/sr unknown
- 2014-03-12 LT LTEP14722008.1T patent/LT2970460T/lt unknown
- 2014-03-12 EP EP20159871.1A patent/EP3683235B1/en active Active
- 2014-03-12 EP EP14722008.1A patent/EP2970460B1/en active Active
- 2014-03-12 PT PT201598711T patent/PT3683235T/pt unknown
- 2014-03-12 US US14/205,512 patent/US9453072B2/en active Active
- 2014-03-12 PL PL14722008T patent/PL2970460T3/pl unknown
- 2014-03-12 DK DK14722008.1T patent/DK2970460T3/da active
- 2014-03-12 ES ES14722008T patent/ES2804592T3/es active Active
- 2014-03-12 EP EP24170532.6A patent/EP4403570A3/en active Pending
- 2014-03-12 MY MYPI2019007720A patent/MY201923A/en unknown
- 2014-03-12 MY MYPI2022005368A patent/MY209528A/en unknown
- 2014-03-12 MY MYPI2015702406A patent/MY174740A/en unknown
- 2014-03-12 HR HRP20240774TT patent/HRP20240774T1/hr unknown
- 2014-03-12 KR KR1020157021200A patent/KR102103159B1/ko active Active
- 2014-03-12 FI FIEP20159871.1T patent/FI3683235T3/fi active
- 2014-03-12 SG SG11201505745WA patent/SG11201505745WA/en unknown
- 2014-03-12 PT PT147220081T patent/PT2970460T/pt unknown
- 2014-03-12 ES ES20159871T patent/ES2983609T3/es active Active
- 2014-03-12 DK DK20159871.1T patent/DK3683235T3/da active
- 2014-03-13 UY UY0001035417A patent/UY35417A/es not_active Application Discontinuation
-
2015
- 2015-07-24 ZA ZA2015/05376A patent/ZA201505376B/en unknown
- 2015-07-24 PH PH12015501656A patent/PH12015501656B1/en unknown
- 2015-08-04 IL IL240354A patent/IL240354A0/en unknown
- 2015-08-17 MX MX2020012416A patent/MX2020012416A/es unknown
- 2015-09-04 CL CL2015002469A patent/CL2015002469A1/es unknown
-
2016
- 2016-08-26 US US15/248,348 patent/US10000564B2/en active Active
-
2018
- 2018-01-12 CL CL2018000101A patent/CL2018000101A1/es unknown
- 2018-05-14 US US15/979,187 patent/US10519230B2/en active Active
- 2018-09-13 IL IL261743A patent/IL261743B/en active IP Right Grant
-
2019
- 2019-02-05 JP JP2019018423A patent/JP6845876B2/ja active Active
- 2019-11-18 US US16/687,257 patent/US11104729B2/en active Active
-
2021
- 2021-07-29 US US17/388,322 patent/US12037388B2/en active Active
-
2024
- 2024-06-05 US US18/734,956 patent/US20240425580A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11530263B2 (en) | IL-18 binding protein (IL-18BP) in inflammatory diseases | |
| JP6845876B2 (ja) | 抗ｉｌ−３３抗体及びその使用 | |
| JP6830533B2 (ja) | 抗ｉｌ−３３抗体およびその使用 | |
| CN110167963A (zh) | 治疗发炎病况的方法 | |
| JP2016515130A5 (enExample) | ||
| JP2020513404A5 (enExample) | ||
| JP2018509153A (ja) | Ｔｓｌｐ結合タンパク質 | |
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| JP2023510972A (ja) | 抗ｓｔ２抗体及びその適用 | |
| TW201620933A (zh) | 抗體－飛諾莫接合物 | |
| JP2022549087A5 (enExample) | ||
| TWI799417B (zh) | 生物製藥組成物及相關方法 | |
| KR20150074179A (ko) | 리실 옥시다제-유사 2 (loxl2)와 관련된 치료 및 진단 방법 | |
| RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
| TW202304980A (zh) | 經修飾的抗ｔｓｌｐ抗體 | |
| KR20200010294A (ko) | 치료용 항-cd40 리간드 항체 | |
| JP2014530836A (ja) | 炎症障害治療用のｉｌ１７ｃのアンタゴニスト | |
| CN104470540B (zh) | 抗-mif抗体和糖皮质激素的联合治疗 | |
| AU2024333809A1 (en) | Klk5/7 + th2 targeting antibodies and uses thereof | |
| WO2017153426A1 (en) | Tslp binding proteins | |
| JP2021533806A5 (enExample) | ||
| JP2018529704A (ja) | アトピー性皮膚炎の治療および／または予防のためのｉｌ−１７ｃの拮抗剤 | |
| US20230365712A1 (en) | Notch4 antibodies and uses thereof | |
| JP2022172170A (ja) | 治療抗ＩｇＥ抗体並びにその方法及び組成物 | |
| Leung et al. | Emerging treatment options in severe asthma |